ライフサイエンスコーパス: University of California

1 National Institutes of Health, University of California, Abbott Laboratories, and the C

2 University of California and the Safeway Foundation.

3 ectal cancer patients from registries at the University of California and Veterans Administration hos

4 e example of collaboration between academia (University of California) and industry (Sangamo), Hoban

5 d up receiving an excellent education at the University of California at Berkeley and postdoctoral tr

6 as a graduate student with Matt Welch at the University of California at Berkeley, my interest was pi

7 se tolerance and diabetes onset in UCD-T2DM (University of California at Davis type 2 diabetes mellit

8 e University of Hawaii and my Ph.D. from the University of California at Davis.

9 erface called Cyber-T that is located on the University of California at Irvine genomics web site.

10 Using a modification of the RAND/University of California at Los Angeles appropriateness

11 ton second chromosome deficiency kit and the University of California at Los Angeles Bruinfly FRT40A-

12 nsecutive liver transplants performed at the University of California at Los Angeles during a 6-year

13 Eight RCC recurrence models (University of California at Los Angeles Integrated Stagi

14 sity of Pennsylvania School of Medicine, the University of California at Los Angeles School of Medici

15 of the Department of Plant Pathology at the University of California at Riverside the same year and

16 in the Rancho Bernardo Study (n=196) and the University of California at San Diego's Filipino Women's

17 ced, malignant, incurable solid tumours from University of California at San Diego, CA, USA, and Sara

18 l developed by the Palsson Laboratory at the University of California at San Diego.

19 rk with 4,396 head CT scans performed at the University of California at San Francisco and affiliated

20 University of California at San Francisco criteria, alph

21 atory bowel disease from 1990 to 2015 at the University of California at San Francisco Medical Center

22 of 417 primary cutaneous melanomas from the University of California at San Francisco Melanoma Cente

23 ornia at Los Angeles School of Medicine, the University of California at San Francisco School of Medi

24 e past 20 years in the Tetrad program at the University of California at San Francisco to identify un

25 lege of Wisconsin, University of Cincinnati, University of California at San Francisco, University of

26 a 5-year longitudinal MS cohort study at the University of California at San Francisco.

27 ndation, Department of Veterans Affairs, and University of California at San Francisco.

28 ment of a tiered museum-based program at the University of California, Berkeley as a model for engagi

29 ods, developed by linguists Johanna Nichols (University of California, Berkeley), Donald Ringe and An

30 rly studies of bees, (c) student work at the University of California, Berkeley, (d) work at the Amer

31 eyer is an acting associate professor at the University of California, Berkeley, and an emergency phy

32 merases continued throughout my years at the University of California, Berkeley, and Harvard.

33 I chose the University of California, Berkeley, for my PhD because i

34 biosynthesis of plant polysaccharides at the University of California, Berkeley, led me, rather impro

35 VIZARD is a Java program created at the University of California, Berkeley, to facilitate analys

36 d by his family, and then transferred to the University of California, Berkeley, to major in entomolo

37 She was an undergraduate at the University of California, Berkeley, where she worked in

38 George Oster is Professor of Biophysics, University of California, Berkeley.

39 ons under the guidance of H.A. Barker at the University of California, Berkeley.

40 s, and coenzymes with Professor Snell at the University of California-Berkeley, it was rational to be

41 weeks (July-Oct 1998) of observations at the University of California, Blodgett Forest field station

42 ly approach, while Christopher Polage of the University of California Davis and Mark Wilcox of Leeds

43 t accrual into cancer clinical trials at the University of California Davis Cancer Center.

44 s published in this issue resulting from the University of California Davis Cardiovascular Symposium

45 group of scientists convened as part of the University of California Davis Cardiovascular Symposium

46 s published in this issue resulting from the University of California Davis Cardiovascular Symposium

47 Prospective observational study at the University of California Davis Medical Center (Sacrament

48 peration within 60 minutes of arrival at the University of California Davis Medical Center.

49 esolution imaging systems constructed at the University of California Davis were used to acquire reti

50 University of California Davis, US Department of Agricul

51 years treated for blunt torso trauma at the University of California, Davis Medical Center, a level

52 of this intervention in 2-mo-old prediabetic University of California, Davis type 2 diabetes mellitus

53 se Control and Prevention, Njala University, University of California, Davis USAID-PREDICT, and the U

54 ducted at the Imaging Research Center of the University of California, Davis, from November 2004 thro

55 31, 2013, at the Vascular Laboratory of the University of California, Davis, Medical Center were inc

56 , through May 31, 2004, was conducted at the University of California, Davis, Medical Center.

57 derwent cutaneous surgical procedures at the University of California, Davis, outpatient dermatology

58 simulation experiments were conducted at the University of California, Davis, research CAFO.

59 ated the effects of leptin administration in University of California, Davis, type 2 diabetes mellitu

60 iversity in Uganda, a sabbatical year in the University of California, Davis, where I became aware of

61 Center for Healthcare Policy and Research, University of California, Davis.

62 ll vial culture currently implemented at the University of California-Davis Medical Center hospital.

63 is a report of a series of 2 patients at the University of California-Davis Medical Center treated be

64 being trained as a plant pathologist at the University of California-Davis, an institution that prid

65 The University of California-Davis_Primary (UCD_P) chemical

66 The University of California-Davis_Primary (UCD_P) model was

67 pecimens were evaluated; 1,806 were from the University of California Irvine Medical Center Medical M

68 December 2, 2010, and June 11, 2012, at the University of California Irvine Medical Center.

69 The 3-dimensional University of California Irvine-California Institute of

70 DOSI instruments were constructed at the University of California, Irvine (Irvine, CA), and deliv

71 ifier outputs, biomedical data sets from the University of California, Irvine (UCI) Machine Learning

72 Testing with datasets from the UCI (University of California, Irvine) Machine Learning Repos

73 In 1984, I moved to the University of California, Irvine, and initiated research

74 National Cancer Institute compounds and the University of California, Irvine, ChemDB database result

75 study of aging and dementia performed at the University of California, Irvine, from January 1, 2003,

76 ies, host plants, and the environment at the University of California, Irvine.

77 ng in patients with BCC was performed at the University of California-Irvine Health Beckman Laser Ins

78 -label, single-arm comparative study done at University of California Los Angeles (Los Angeles, CA, U

79 The University of California Los Angeles (UCLA) and Universi

80 Between August 2012 and May 2013, the University of California Los Angeles (UCLA) preschool vi

81 A retrospective analysis (University of California Los Angeles [n = 145], Houston

82 e recommendations using the RAND Corporation-University of California Los Angeles Appropriateness Met

83 nts out of 661 undergoing nephrectomy at the University of California Los Angeles between 1989 and 19

84 ds of 661 patients undergoing nephrectomy at University of California Los Angeles between 1989 and 19

85 trisegment graft that were performed at the University of California Los Angeles between 9/91 and 02

86 aparoscopic donor nephrectomies performed at University of California Los Angeles between August 1999

87 nts were identified from the database of the University of California Los Angeles Kidney Cancer Progr

88 lth Survey and a validated short form of the University of California Los Angeles Prostate Cancer Ind

89 ersity of Southern California and the Harbor University of California Los Angeles Research and Educat

90 usetts General Hospital, Boston, MA, and the University of California Los Angeles, Ronald Reagan Medi

91 Research AND Development Corporation (RAND)/University of California, Los Angeles (UCLA) Appropriate

92 luded studies performed after I moved to the University of California, Los Angeles (UCLA), including

93 uate students in an organized program at the University of California, Los Angeles (UCLA), we have un

94 The data coordinating centre at the University of California, Los Angeles (UCLA, CA, USA), r

95 Patients with advanced HF referred to University of California, Los Angeles (UCLA; n=2255), we

96 Center for Advancing Translational Science (University of California, Los Angeles [CA, USA] Clinical

97 asures for validity on the basis of the RAND/University of California, Los Angeles Appropriateness Me

98 We used the RAND Corporation/University of California, Los Angeles Appropriateness Me

99 obtained from all patients undergoing ITx at University of California, Los Angeles from July 2008 to

100 merica at the Jules Stein Eye Institute, the University of California, Los Angeles in 2004.

101 ear period at the Seizure Disorder Center at University of California, Los Angeles in the USA (45 pat

102 oduce integrated staging systems such as the University of California, Los Angeles Integrated Staging

103 blation procedures (n=24; 50% paroxysmal) at University of California, Los Angeles Medical Center wer

104 ective/Management (LENT/SOM) scales, and the University of California, Los Angeles Prostate Cancer In

105 d, leaving a 34-item revised instrument (the University of California, Los Angeles Scleroderma Clinic

106 tients pursuing transplant evaluation at the University of California, Los Angeles Transplant Program

107 ed Glaucoma Intervention Study and the UCLA (University of California, Los Angeles) Jules Stein Eye I

108 was designed by Wu Lab (School of Dentistry, University of California, Los Angeles) to measure the di

109 0, 2017, at the Stein Eye Institute at UCLA (University of California, Los Angeles).

110 the Department of Pathology Registry at the University of California, Los Angeles, and analyzed for

111 founded the Jules Stein Eye Institute at the University of California, Los Angeles, and led a multiye

112 1 KEYNOTE-001 trial at a single institution (University of California, Los Angeles, CA, USA).

113 agnosed, suspected genetic conditions at the University of California, Los Angeles, Clinical Genomics

114 ile they were undergoing hemodialysis at the University of California, Los Angeles, dialysis center.

115 microPET, was designed and developed at the University of California, Los Angeles, for imaging small

116 ollected at the Department of Ophthalmology, University of California, Los Angeles, from May 1 to Jul

117 rked on diseases of ornamental plants at the University of California, Los Angeles, starting in 1939,

118 ruary 1, 1990, and November 30, 2010, at the University of California, Los Angeles, were matched in a

119 99 to April 2012 at the Stein Eye Institute, University of California, Los Angeles.

120 the Ahmanson-Lovelace Brain Mapping Center, University of California, Los Angeles.

121 control individuals from 2015 to 2016 at the University of California, Los Angeles.

122 A University of California, Los Angeles/Kaiser Permanente

123 vely, compared to 21.1 and 7.6 months in the University of California, Los Angeles/KPLA control cohor

124 oved PFS without improved OS compared to the University of California, Los Angeles/KPLA control group

125 2 rounds on a scale of 1 to 9 using the RAND/University of California-Los Angeles modified-Delphi met

126 Data were derived from the University of California Lupus Outcomes Study, a longitu

127 CT examinations in 2609 children at the five University of California medical centers during 2013.

128 A key secondary measure was the University of California Performance-based Assessment-Ex

129 composition are revisited using 15 years of University of California, Riverside/CE-CERT environmenta

130 ion (MASC), and functional capacity with the University of California San Diego Performance-Based Ski

131 an (GM) ordered between 2013 and 2019 at the University of California San Diego, the Medical Universi

132 nge in 6-min walk distance (6MWD), change in University of California San Diego-Shortness of Breath Q

133 SETTING: Hamilton Glaucoma Center, University of California San Diego.

134 horts: mainly non-severe asthmatics from the University of California San Francisco (UCSF) and mainly

135 versity of California Los Angeles (UCLA) and University of California San Francisco (UCSF) codevelope

136 Using a combination of FDG-PET and University of California San Francisco (UCSF) criteria,

137 n Criteria and an additional 26 (10%) within University of California San Francisco (UCSF) criteria.

138 from June 3, 2012, to April 26, 2014, at the University of California San Francisco (UCSF) Medical Ce

139 The third cohort of 120 patients from the University of California San Francisco (UCSF) was includ

140 re grouped by tumor size according to Milan, University of California San Francisco (UCSF), and outsi

141 h advanced fibrosis in the discovery cohort (University of California San Francisco [UCSF], N = 433),

142 The Committee of Human Research of the University of California San Francisco approved this stu

143 includes 243 listed (105 M+ group, 76 beyond University of California San Francisco criteria; 210 tra

144 iverse ambulatory nephrology practice at the University of California San Francisco during calendar y

145 (68)Ga-PSMA-11 PET studies performed at the University of California San Francisco from October 2015

146 In 1996, the University of California San Francisco Gynecologic Oncol

147 isk of death in four intensive care units at University of California San Francisco Medical Center fr

148 ted at San Francisco General Hospital or the University of California San Francisco Medical Center.

149 A data set of 526 patients from the University of California San Francisco Melanoma Center w

150 isease AAO in an independent cohort from the University of California San Francisco Memory and Aging

151 We screened the University of California San Francisco Memory and Aging

152 e (SICCA) who presented for follow-up at the University of California San Francisco, Aravind Eye Hosp

153 c hypersensitivity pneumonitis, one from the University of California San Francisco, CA, USA (UCSF),

154 ter, Dallas, TX; Dr. Elizabeth H. Blackburn, University of California San Francisco, CA; and Dr. Mari

155 016 were reviewed from 3 transplant centers (University of California San Francisco, Mayo Clinic Flor

156 007 in the neuro-ophthalmology clinic at the University of California San Francisco.

157 , 308 LRT and 120 LURT were performed at the University of California San Francisco.

158 due to IgA nephropathy were performed at the University of California San Francisco.

159 nalysis, [GPA]) and 21 healthy eyes from the University of California, San Diego (UCSD) Diagnostic In

160 ts from June 2003 until December 2009 at the University of California, San Diego (UCSD), Medical Cent

161 uenza A virus within the student body of the University of California, San Diego (UCSD), sampling for

162 ment to assess decision-making capacity: the University of California, San Diego Brief Assessment of

163 r =4 retinal tomographic examinations in the University of California, San Diego Diagnostic Innovatio

164 a reliable objective measure of functioning [University of California, San Diego Performance-Based Sk

165 Dyspnea Index total score or 5 units in the University of California, San Diego Shortness of Breath

166 efined by 48-week worsening of FVC, dyspnea (University of California, San Diego Shortness of Breath

167 wed up at the Visual Performance Laboratory, University of California, San Diego, at 6-month interval

168 ial conducted at an academic medical center, University of California, San Diego, between July 2011 a

169 controls were taken on a 25-min walk on the University of California, San Diego, campus during which

170 ination were obtained and transferred to the University of California, San Diego, Data Coordinating C

171 d for up to 6 years in cohort studies at the University of California, San Diego, HIV Neurobehavioral

172 arold Varmus and Roel Nusse, was held at the University of California, San Diego, in June 2007.

173 rials from March 2001 to October 2012 at the University of California, San Diego, Medical Center in L

174 At the University of California, San Diego, Medical Center, our

175 ic and Mohs Micrographic Surgery Unit of the University of California, San Diego, Medical Center.

176 and functional capacity, as measured by the University of California, San Diego, Performance-Based S

177 Total scores on the University of California, San Diego, Performance-Based S

178 vities of daily living, as measured with the University of California, San Diego, Performance-Based S

179 A symposium was held at the University of California, San Diego, to honor the contri

180 University, The Netherlands) and Yunde Zhao (University of California, San Diego, USA).

181 rs at the Alzheimer Disease Research Center, University of California, San Diego.

182 ildren at San Diego State University and the University of California, San Diego.

183 ed or suspect glaucoma were recruited at the University of California, San Diego.

184 from a longitudinal prospective study at the University of California, San Diego.

185 ducted at the Visual Performance Laboratory, University of California, San Diego.

186 University of California, San Diego.

187 ase-control studies in the United States and University of California, San Francisco (1991-2004)) and

188 =5 cm or </=3 nodules measuring </=3 cm) and University of California, San Francisco (single tumor me

189 maximum of 3 total tumors with none >3 cm), University of California, San Francisco (UCSF) criteria

190 likely to have 1 lesion, tumors within Milan/University of California, San Francisco (UCSF) criteria,

191 [CN] controls) from the San Francisco-based University of California, San Francisco (UCSF) Memory an

192 les from 51 patients with RA enrolled in the University of California, San Francisco (UCSF) RA Cohort

193 ing these financial threats, research at the University of California, San Francisco (UCSF), has unde

194 ata from 338 BAVM cases participating in the University of California, San Francisco (UCSF)-Kaiser Br

195 ans of NBS for SCID who received care at the University of California, San Francisco (UCSF).

196 y Prostate Active Surveillance Study (PASS); University of California, San Francisco (UCSF); and Univ

197 recruited patients scheduled for DBS at the University of California, San Francisco and the San Fran

198 uited consecutively from 2001 to 2013 at the University of California, San Francisco and the Universi

199 VGKCc/LGI1-Ab encephalitis evaluated in the University of California, San Francisco Autoimmune Encep

200 tion (HSCT) in two patients with ALSP at the University of California, San Francisco between January

201 valuated at the Multiple Sclerosis Center at University of California, San Francisco between July 200

202 of Biostatistics He is also a member of the University of California, San Francisco Cardiovascular R

203 r Health Policy Studies and Co-leader of the University of California, San Francisco Comprehensive Ca

204 We identified 36 186 ECGs from the University of California, San Francisco database that wo

205 th hepatocellular carcinoma (HCC) within the University of California, San Francisco down-staging (UC

206 with MS/clinically isolated syndrome in the University of California, San Francisco EPIC cohort stud

207 Providers at University of California, San Francisco have been at the

208 sly secret tobacco industry documents in the University of California, San Francisco Legacy Tobacco D

209 pus erythematosus (SLE) participating in the University of California, San Francisco Lupus Outcomes S

210 Data were derived from the University of California, San Francisco Lupus Outcomes S

211 Chapel Hill), and cardiology training at the University of California, San Francisco Medical Center.

212 t the pediatric multiple sclerosis center of University of California, San Francisco or State Univers

213 The present study uses data from the University of California, San Francisco RA Panel Study i

214 The present study uses data from the University of California, San Francisco RA Panel Study,

215 sed 231 women with RA who are members of the University of California, San Francisco RA Panel Study.

216 obacco Control Research and Education at the University of California, San Francisco School of Medici

217 (MK) has been organizing Eco Seminars at the University of California, San Francisco since 2019.

218 10 and who radiologically met Milan or UCSF (University of California, San Francisco) criteria, 1-yea

219 sed molecular graphics package UCSF CHIMERA (University of California, San Francisco).

220 radiographic images from 179 aneurysm cases (University of California, San Francisco, 1990--1997) to

221 ed at teaching hospitals affiliated with the University of California, San Francisco, and a required

222 at the Hunters Point Animal Facility at the University of California, San Francisco, and all experim

223 Mexico's Ministry of Health, University of California, San Francisco, and Bill & Meli

224 at Aravind Eye Hospital, Proctor Foundation, University of California, San Francisco, and Dartmouth-H

225 University of California, San Francisco, and Institute f

226 s of a study of postdoctoral outcomes at the University of California, San Francisco, and suggest tha

227 University of California, San Francisco, and the U.S. De

228 itial conformations generated by CombiBuild (University of California, San Francisco, CA, 1995), we h

229 were enrolled in the intensive care units at University of California, San Francisco, CA, USA, Stanfo

230 with HCC larger than the proposed Milan and University of California, San Francisco, criteria experi

231 children with HCC larger than the Milan and University of California, San Francisco, criteria.

232 ively recruited from glaucoma clinics at the University of California, San Francisco, from January 20

233 3 University of California, San Francisco, hospitals.

234 stematic application of fetal surgery at the University of California, San Francisco, in the early 19

235 approved by and executed in accordance with University of California, San Francisco, institutional a

236 This retrospective case series at the University of California, San Francisco, Medical Center,

237 review of 2397 patients who were seen at the University of California, San Francisco, Memory and Agin

238 d patients with progranulin mutations at the University of California, San Francisco, Memory and Agin

239 ted from electronic medical records from the University of California, San Francisco, Multiple Sclero

240 ed in the Cardiovascular Research Institute, University of California, San Francisco, on blood sample

241 diverse referred sample of women seen at the University of California, San Francisco, Polycystic Ovar

242 The present study uses data from the University of California, San Francisco, RA Panel Study

243 (1997 and 1998) through interviews with the University of California, San Francisco, RA panel.

244 The study was conducted in the University of California, San Francisco, Retina Clinic b

245 ted over 3 years through interviews with the University of California, San Francisco, Rheumatoid Arth

246 targeted NGS using the UCSF500 Cancer Panel (University of California, San Francisco, San Francisco,

247 academic tertiary referral medical centers: University of California, San Francisco, University of P

248 east GFP fusion localization database by the University of California, San Francisco, USA (UCSF).

249 Men managed with AS at University of California, San Francisco, were classified

250 and Bharatpur Eye Hospital in Nepal, and the University of California, San Francisco, who had culture

251 o were receiving maintenance hemodialysis at University of California, San Francisco-affiliated dialy

252 to radiation and were treated surgically at University of California, San Francisco-affiliated hospi

253 recruited from ophthalmology clinics at the University of California, San Francisco.

254 SETTING Memory and Aging Center, University of California, San Francisco.

255 ents with non-squamous NSCLC resected at the University of California, San Francisco.

256 between September 1996 and December 2003 at University of California, San Francisco.

257 stitutes of Health ARDS Network trial at the University of California, San Francisco.

258 orenstein Endowed Chair in Cardiology at the University of California, San Francisco.

259 e performed at the Mission Bay Campus of the University of California, San Francisco.

260 Canadian Institutes of Health Research; and University of California, San Francisco.

261 ing Center of the Department of Neurology at University of California, San Francisco.

262 er Center and the Mt Zion Health Fund of the University of California, San Francisco.

263 ce of pathologic HCC findings outside of the University of California-San Francisco criteria (P=0.001

264 ed from the Multiple Sclerosis Center at the University of California-San Francisco.

265 2 and 2012 at 3 academic transplant centers (University of California-San Francisco; Mayo Clinic, Roc

266 bstantial false positives in the widely used University of California Santa Cruz (UCSC) annotations,

267 The University of California Santa Cruz (UCSC) Gene Sorter h

268 The University of California Santa Cruz (UCSC) Genome Bioinf

269 small virtual machine version of the popular University of California Santa Cruz (UCSC) Genome Browse

270 ed, configured and fully integrated into the University of California Santa Cruz (UCSC) Genome Browse

271 The University of California Santa Cruz (UCSC) Genome Browse

272 The University of California Santa Cruz (UCSC) Genome Browse

273 The University of California Santa Cruz (UCSC) Genome Browse

274 The University of California Santa Cruz (UCSC) Known Genes d

275 The University of California Santa Cruz (UCSC) Proteome Brow

276 The University of California Santa Cruz (UCSC) Table Browser

277 echnology Information, Genome Browser at the University of California Santa Cruz and the disease port

278 University of California Santa Cruz genome browser analy

279 The University of California Santa Cruz Genome Browser Datab

280 The variation resources within the University of California Santa Cruz Genome Browser inclu

281 The University of California Santa Cruz Genome Browser offer

282 use publicly available data tracks from the University of California Santa Cruz Genome Browser to in

283 results can be visualized locally or in the University of California Santa Cruz Genome Browser.

284 promoter retrieval and visualization in the University of California Santa Cruz Genome Browser.

285 the Wellcome Trust Sanger Institute and the University of California Santa Cruz, provide coordinated

286 and intuitive programmatic interface to the University of California, Santa Cruz (UCSC) genome brows

287 The University of California, Santa Cruz (UCSC) Genome Brows

288 Since its 2001 debut, the University of California, Santa Cruz (UCSC) Genome Brows

289 The University of California, Santa Cruz (UCSC) Interaction

290 The ENCODE Data Coordination Center at The University of California, Santa Cruz (UCSC) is the prima

291 3), two consecutive releases by the IHGSC at University of California, Santa Cruz (UCSC), two consecu

292 of the annotation tracks are computed at the University of California, Santa Cruz from publicly avail

293 The University of California, Santa Cruz Genome Browser Data

294 The University of California, Santa Cruz Genome Browser offe

295 ENCODE Data Coordination Center (DCC) at the University of California, Santa Cruz serves as the centr

296 The University of California, Santa Cruz, Genome Browser Dat

297 A microfluidic device is being developed by University of California-Santa Barbara as part of a join

298 l, a decision by Stanford University and the University of California to seek patents on the technolo

299 scribe the impact my graduate studies at the University of California (UC)-Davis had on my career.

300 The analysts from the University of California who conducted the medical effec